Blum, Andreas, Loerz, Christine, Martin, Hans-Joerg, Staab-Weijnitz, Claudia A. and Maser, Edmund (2012) Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor. Journal of Steroid Biochemistry and Molecular Biology, 128 (1-2). pp. 51-55.

Full text not available from this repository.

Abstract

11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) catalyzes the intracellular regeneration of active cortisol from inert cortisone in key metabolic tissues, thus regulating ligand access to glucocorticoid receptors. There is strong evidence that increased adipose 11 beta-HSD1 activity may be an important aetiological factor in the current obesity and diabetes type 2 epidemics. Hence, inhibition of 11 beta-HSD1 has emerged as a promising anti-diabetic strategy, a concept that is largely supported by numerous studies in rodent models as well as limited clinical data with prototype inhibitors. Momordica charantia (also known as bitter melon, bitter gourd or karela) is traditionally used for treatment of diabetes in Asia, South America, the Caribbean, and East Africa. In the present study, we show that M. charantia extract capsules contain at least one ingredient with selective 11 beta-HSD1 inhibitory activity. The finding constitutes an interesting additional explanation for the well-documented anti-diabetic and hypoglycaemic effects of M. charantia. (C) 2011 Elsevier Ltd. All rights reserved.

Document Type:	Article
Research affiliation:	OceanRep > The Future Ocean - Cluster of Excellence Kiel University
Projects:	Future Ocean
Date Deposited:	14 May 2014 10:21
Last Modified:	14 May 2014 10:21
URI:	https://oceanrep.geomar.de/id/eprint/23838

Actions (login required)

View Item